RESEARCH · RETATRUTIDE · SLEEP APNOEA AND KNEE OSTEOARTHRITIS
Retatrutide in Obstructive Sleep Apnoea and Knee Osteoarthritis: What the TRIUMPH Basket Trials Report
PurixLab’s Retatrutide 10mg is a research vial of the investigational GIP, GLP-1 and glucagon receptor triple agonist. Our earlier articles cover the clinical trial series, safety and tolerability and type 2 diabetes and the kidney. This article looks at two obesity-related conditions that the phase 3 TRIUMPH programme was built to test: obstructive sleep apnoea (OSA) and knee osteoarthritis. These are published findings about an investigational drug studied under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Why these two conditions?
Both conditions are closely tied to body weight. In a population cohort of employed Wisconsin adults studied twice at 4-year intervals, a 10% weight gain predicted an approximate 32% increase in the apnoea-hypopnoea index (AHI), and a 10% weight loss predicted a 26% decrease [1]. For the knee, a meta-analysis of four randomised trials with 454 patients found that physical disability could be significantly improved when weight was reduced by more than 5.1%, while the pain response was less predictable [2]. In the 18-month IDEA trial, intensive diet plus exercise produced an 11.4% mean weight loss, with less pain and better function than diet or exercise alone, and diet-induced weight loss lowered knee compressive forces [3]. A drug that produces large weight loss is therefore a logical candidate for both conditions, and the question is how large and how consistent the effect is.
The TRIUMPH basket design
TRIUMPH consists of four phase 3, randomised, double-blind, placebo-controlled studies in more than 5800 participants. Two weight-management trials, TRIUMPH-1 and TRIUMPH-2, contain nested OSA and/or knee osteoarthritis protocols; TRIUMPH-3 enrols people with cardiovascular disease, and TRIUMPH-4 is a stand-alone osteoarthritis trial. The primary endpoint is the change in AHI for OSA and includes the WOMAC pain subscale for knee osteoarthritis, with the type I error rate split between the weight-management analysis and each basket [4]. The design lets one large trial answer several questions, but each nested sub-study is smaller than the parent trial.
Before phase 3, the 48-week phase 2 obesity trial had enrolled 338 adults and reported weight changes of up to 24.2% in the highest group versus 2.1% with placebo, with gastrointestinal events the most common adverse events [5]. That trial did not report sleep or joint endpoints.
Knee osteoarthritis in TRIUMPH-1
TRIUMPH-1 randomised 2339 adults with obesity but without diabetes for 80 weeks. Mean body weight changes were -17.6%, -23.7% and -25.0% across the three retatrutide strengths, versus -3.9% with placebo. Among 574 participants with knee osteoarthritis, the WOMAC pain score, on a scale the authors describe as ranging from 1 to 10, fell by 3.2, 3.5 and 3.6 points versus 1.9 with placebo under the hybrid estimand; the differences for the two co-primary strengths were 1.6 and 1.8 points. Under the intention-to-treat estimand the corresponding differences were 1.4 and 1.6 points [6].
A useful comparison is STEP 9, a 68-week trial of semaglutide in 407 people with obesity and moderate knee osteoarthritis, where body weight changed by -13.7% versus -3.2% and the WOMAC pain score (0 to 100 scale) by -41.7 versus -27.5 points [7]. Both trials show a sizeable placebo response on pain, which is typical of symptom-based endpoints. The two programmes used different pain scales, populations and estimands, so their numbers should not be compared directly.
Obstructive sleep apnoea in TRIUMPH-1-OSA and TRIUMPH-2-OSA
The OSA results come from two trials nested within the basket studies: TRIUMPH-1-OSA (243 participants without type 2 diabetes) and TRIUMPH-2-OSA (448 participants with type 2 diabetes), all with moderate-to-severe OSA. Baseline AHI was high, at 58.6 and 55.9 events per hour, and mean body weight was 119.6 and 115.9 kg. At 80 weeks, AHI changed by -22.9, -34.3 and -31.7 events per hour with retatrutide in TRIUMPH-1-OSA versus -9.9 with placebo, and by -19.2, -24.7 and -25.4 versus -10.3 in TRIUMPH-2-OSA. For the two co-primary strengths, placebo-adjusted differences were -24.4 and -21.9 events per hour without diabetes, and -14.4 and -15.1 with diabetes. Body weight fell by 12.5% to 22.2% and 12.1% to 18.5% respectively, versus 4.8% and 5.6% with placebo [8].
Two patterns stand out. First, the higher strength did not give a larger AHI reduction than the middle strength in the population without diabetes. Second, both weight loss and AHI reduction were smaller in participants with type 2 diabetes, mirroring the parent trials, where weight fell by 11.9% to 18.8% in TRIUMPH-2 (obesity with type 2 diabetes) compared with 17.6% to 25.0% in TRIUMPH-1 [9,6].
For context, the SURMOUNT-OSA trials of tirzepatide (discussed in our tirzepatide OSA article) ran for 52 weeks with baseline AHI of 51.5 and 49.5 events per hour and reported treatment differences of -20.0 and -23.8 events per hour, together with improvements in hypoxic burden, hsCRP, systolic blood pressure and patient-reported sleep outcomes [10]. The retatrutide OSA abstract reports AHI and body weight; the TRIUMPH abstracts we reviewed do not give the same set of secondary sleep outcomes, so a like-for-like comparison is not yet possible.
Tolerability in the same programme
In all three TRIUMPH reports the most common adverse events were gastrointestinal [6,8,9]. The parent TRIUMPH-2 trial, which randomised 1152 adults with obesity and type 2 diabetes, also reported more hypotension and dysesthesia with retatrutide than with placebo, and more discontinuations due to adverse events at the two higher strengths [9].
Reading this literature critically
- Estimands. OSA and osteoarthritis endpoints used a hybrid estimand, with intention-to-treat results reported alongside; the two give similar but not identical numbers [6,8].
- Surrogate endpoints. The AHI counts events per hour and does not capture symptoms or cardiovascular outcomes, and WOMAC pain is self-reported; neither trial measured joint structure.
- Weight versus direct effects. Observational and diet trials show that weight loss alone changes both conditions [1,3], and the published abstracts do not separate weight-mediated from weight-independent effects.
- Sponsor and status. The TRIUMPH trials were funded by Eli Lilly, and retatrutide remains investigational [8,6].
What remains open
- Results of the stand-alone knee osteoarthritis trial, TRIUMPH-4, and the cardiovascular-disease population in TRIUMPH-3: as of 25 October 2026 we found no PubMed record of either.
- Whether OSA improvements persist after treatment stops, and how retatrutide interacts with positive airway pressure therapy.
- Whether the glucagon receptor component adds anything for these conditions beyond the weight loss itself.
Retatrutide 10mg at PurixLab
Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21. PubMed 11122588 · doi:10.1001/jama.284.23.3015
- Christensen R, Bartels EM, Astrup A, et al. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007;66(4):433-9. PubMed 17204567 · PMC1856062 · doi:10.1136/ard.2006.065904
- Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263-73. PubMed 24065013 · PMC4450354 · doi:10.1001/jama.2013.277669
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. PubMed 41090431 · PMC12673447 · doi:10.1111/dom.70209
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PubMed 42814954 · doi:10.1056/NEJMoa2604169
- Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. PubMed 39476339 · doi:10.1056/NEJMoa2403664
- Grunstein RR, Somers VK, Azarbarzin A, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. N Engl J Med. 2026. PubMed 42904878 · doi:10.1056/NEJMoa2611477
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PubMed 42810372 · doi:10.1016/S0140-6736(26)01861-1
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PubMed 38912654 · PMC11598664 · doi:10.1056/NEJMoa2404881